Stockscreener 앱 받기
1.42
5.33%
-0.08
시장 영업 전:
1.44
0.02
+1.41%
전일 마감가:
$1.50
열려 있는:
$1.63
하루 거래량:
380.88K
Relative Volume:
0.64
시가총액:
$37.10M
수익:
$521.00K
순이익/손실:
$-8.53M
주가수익비율:
-0.5512
EPS:
-2.5762
순현금흐름:
$-7.71M
1주 성능:
+10.94%
1개월 성능:
-8.39%
6개월 성능:
-86.73%
1년 성능:
-53.44%
1일 변동 폭
$1.40
$1.65
1주일 범위
$1.13
$1.75
52주 변동 폭
$1.11
$99.75
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
명칭
Novabay Pharmaceuticals Inc
전화
510-899-8800
주소
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
1.42 | 39.19M | 521.00K | -8.53M | -7.71M | -2.5762 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-09-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 재확인 | Laidlaw | Buy |
| 2017-06-05 | 개시 | ROTH Capital | Buy |
| 2017-03-27 | 개시 | Laidlaw | Buy |
| 2017-02-06 | 개시 | Rodman & Renshaw | Buy |
| 2016-03-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-14 | 재확인 | Maxim Group | Buy |
| 2015-04-30 | 재개 | Maxim Group | Buy |
| 2013-03-06 | 개시 | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | 개시 | Dawson James | Speculative Buy |
모두보기
Novabay Pharmaceuticals Inc 주식(NBY)의 최신 뉴스
NovaBay rebrands to Stablecoin Development Corp in full crypto pivot—pharma company's stock climbs 19% - MSN
Aug Macro: Can NovaBay Pharmaceuticals Inc beat the S P 5002026 Analyst Calls & Fast Exit Strategy with Risk Control - baoquankhu1.vn
NovaBay Pharmaceuticals (NBY) Soars 19% Following Stablecoin Transformation Announcement - mexc.co
NovaBay Pharmaceuticals (NBY) Stock Jumps 19% on Stablecoin Pivot - MEXC
NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19% - Benzinga
Eyecare biotech jumps 19% after stablecoin-focused pivot - TradingView
NovaBay Pharmaceuticals Pivots to Stablecoins in Rebrand - Yahoo Finance
Pharmaceutical Stock Jumps 26% on Crypto Pivot Plan - Blockonomi
Biotech stock NovaBay jumps 19% amid pivot, rebrand to Stablecoin Development Corporation - The Block
Pharmaceutical stock surges 26% after crypto pivot - thestreet.com
NovaBay Rebrands as 'Stablecoin Development Corporation' With Nearly 9% of SKY Supply - thedefiant.io
Stablecoin Development Corp (SDEV): Former NovaBay Completes $147M SKY Token Acquisition and Corporate Rebrand - Blockonomi
NovaBay Pharmaceuticals to Rebrand as Stablecoin Development Corporation, Announces SKY Token Holdings and NYSE Ticker Change to SDEV 121314181920 - Minichart
NovaBay Pharmaceuticals shares are trading hi... - Benzinga
NovaBay Pharma Becomes SDEV, Bets $134M on Sky Protocol Token - Whalesbook
NovaBay Pharmaceuticals (NBY) Stock: Rebrands as Stablecoin Development Corp, Acquires $147M in SKY Tokens - CoinCentral
NovaBay Pharmaceutical (NBY) pivoting to crypto - CoinDesk
NovaBay Rebrands To Stablecoin Development Corp, Shares Jump 12 Percent - Yahoo Finance
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update - Bitget
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports ... - Bluefield Daily Telegraph
After $134M deal, NovaBay rebrands around 2.06B SKY tokens - Stock Titan
If You Invested $1,000 in Novabay Pharma (NBY) - Stock Titan
NBY Stock Price, Quote & Chart | NOVABAY PHARMACEUTICALS INC (NYSEARCA:NBY) - ChartMill
NovaBay Pharmaceuticals, Inc. 2025 Annual Report: Financials, Stock Warrants, Preferred Stock, and Corporate Actions - Minichart
NovaBay Pharmaceuticals 10-K: $0.6M Revenue, $(3.80) EPS, heavy net loss - TradingView
NovaBay (NYSE: NBY) pivots from pharma to SKY token and digital assets - Stock Titan
Taxes of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Total assets of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView
Non-controlling/minority interest of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Preferred dividends of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Preferred dividends of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Net income of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
NovaBay Pharmaceuticals shareholders approve charter amendments and stock issuance By Investing.com - Investing.com Nigeria
EBITDA margin % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Asset turnover of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Book value per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Total debt per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Revenue per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Operating margin % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Return on invested capital % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
CapEx per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Operating cash flow per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Tangible book value per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Enterprise value to EBITDA ratio of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Non-operating income (total) of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView
Gross profit of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
Diluted shares outstanding of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView
NovaBay Pharmaceuticals Approves Issuance of 837 Million Shares and 2026 Equity Incentive Plan in Shareholder Vote - Minichart
NovaBay Pharmaceuticals shareholders approve charter amendments and stock issuance - Investing.com UK
NovaBay Pharma Expands Share Capital and Governance Flexibility - TipRanks
NovaBay (NYSE: NBY) OKs 5B share authorization and charter changes - Stock Titan
Novabay Pharmaceuticals Inc (NBY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):